Latest News

In recent days, Deutsche Bank downgraded Norfolk Southern to a Hold rating, signaling increased caution around the railroad operator’s outlook and operations. At the same time, a meaningful reduction in short interest suggests some bearish investors have scaled back their positions, hinting at a shift in market sentiment. We’ll now examine how Deutsche Bank’s downgrade may influence Norfolk Southern’s existing investment narrative and future risk‑reward balance. Uncover the next big thing...

Ramelius Resources has launched a A$250 million share buyback program, approved on 10 December 2025, to repurchase up to 73,964,497 shares (3.84% of its 1,924,864,769 issued shares) by June 2027 as a way of returning capital to investors. Alongside the buyback, Ramelius has lifted its minimum annual dividend to 2 cents per share and outlined a 5‑year growth plan targeting higher gold production, signalling confidence in cash generation and business expansion plans. We’ll now examine how...

Deutsche Bank (XTRA:DBK) has quietly turned into one of Europe’s stronger bank stock stories, with the share price nearly doubling over the past year and comfortably outpacing the wider financial sector. See our latest analysis for Deutsche Bank. That strength is not just a short burst either, with a near 94% year to date share price return and a roughly 300% five year total shareholder return signalling powerful momentum as markets reassess Deutsche Bank’s earnings power and risk profile. If...

BWP Trust (ASX:BWP) has just guided to a higher half year payout, flagging a preliminary distribution of 9.58 cents per stapled security, up about 4% on the prior period. See our latest analysis for BWP Trust. The upbeat distribution guidance has landed against a supportive backdrop, with the share price at A$3.93 and an 18.73% year to date share price return pointing to rebuilding momentum, while the 1 year total shareholder return of 24.92% underlines how income plus modest growth has...

Earlier this month, several analysts upgraded Lear Corporation after management indicated fourth-quarter 2025 results should land at the upper end of guidance and flagged a return to positive revenue and earnings growth next year, supported by reshoring, deeper Chinese OEM exposure and automation-led cost savings. At the same time, one major bank downgraded its rating, so the overall picture now reflects growing optimism around Lear’s operational improvements while still highlighting...

Kewaunee Scientific (KEQU) has just turned in a mixed Q2 2026 scorecard, posting revenue of about $70.1 million and EPS of $0.85 as profitability continues to reflect a narrower net margin profile than a year ago. The company has seen quarterly revenue move from $47.8 million in Q2 2025 to $70.1 million in Q2 2026, while quarterly EPS has swung between $0.47 and $1.70 over the same stretch, underscoring how choppy earnings have become as margins compressed from last year’s levels. See our...

In late November 2025, Ørsted and other clean-energy groups won a US federal court ruling that declared President Donald Trump’s ban on new wind projects unlawful, removing a legal barrier to future developments. This decision not only supports Ørsted’s US offshore wind ambitions but also highlights how judicial outcomes can materially influence long-term project visibility and confidence. Next, we’ll examine how this court victory on the US wind project ban shapes Ørsted’s investment...

Earlier this month, The GEO Group Inc. announced that long‑time Senior Vice President, Legal Services, General Counsel, and Corporate Secretary Joe Negron will retire effective December 31, 2025, after serving in his current roles since 2019, and will remain as a consultant on legal, regulatory, and compliance matters for two years starting January 1, 2026. This transition keeps Negron’s institutional and regulatory expertise tied to GEO as investor attention increasingly centers on the...

Praxis Precision Medicines (PRAX) just checked several big regulatory boxes, with the FDA signaling a path toward New Drug Applications for relutrigine and ulixacaltamide while elsunersen’s EMBRAVE3 trial shifts into a faster single arm design. See our latest analysis for Praxis Precision Medicines. Those rapid fire regulatory wins have gone hand in hand with a powerful rerating, with Praxis posting a roughly 609% 3 month share price return and a 627% 3 year total shareholder return,...

T. Rowe Price Group recently reported that its assets under management stood at US$1.79 trillion at the end of November, alongside US$8.0 billion in net client outflows for the month, while also reshaping operations with a new Technology, Data, and Operations function. These sizable outflows, combined with organizational changes and ongoing investment in technology and global distribution, highlight the tension between the firm’s strong retirement franchise and current pressure on organic...

Repligen (RGEN) is back in focus after fresh coverage spotlighted a growing disconnect between its acquisition driven expansion and softer organic revenue growth, along with a clear slide in operating margins. See our latest analysis for Repligen. The latest note seems to have cooled sentiment a little, with a modest pullback in the 7 day share price return after a strong 90 day share price rally and only lukewarm 1 year total shareholder return. This hints that momentum is still rebuilding...

SSR Mining recently outlined its plans for a potential restart of the Çöpler mine in Türkiye, contingent on regulatory approvals and additional environmental remediation commitments following earlier operational disruptions. This potential restart highlights how the company’s diversified portfolio could help balance regulatory and environmental risks while restoring exposure to a key gold-producing asset. We’ll now examine how the possible Çöpler restart and its regulatory complexities...

Daktronics (DAKT) just stacked several important updates into one quarter, combining solid Q2 sales and order growth with a deeper product backlog, a new CEO on deck, and expanded manufacturing capacity. See our latest analysis for Daktronics. That operational momentum is starting to show up in the market too, with the share price at around $20.51 and a robust year to date share price return of roughly 23%, building on a remarkable three year total shareholder return above 700%. If Daktronics...

Earlier this month, Novo Nordisk presented topline phase 3 Evoke and Evoke+ results for oral semaglutide in Alzheimer’s disease, showing statistically significant but clinically modest biomarker reductions and no success on the primary endpoints, while also completing its US$5.20 billion acquisition of Akero Therapeutics and advancing multiple obesity-drug initiatives. Although the Alzheimer’s data fell short clinically, the biomarker insights, expanding obesity pipeline, and new...

If you are wondering whether Cleveland-Cliffs at around $13.41 is a bargain or a value trap right now, you are not alone. This breakdown is designed to help you cut through the noise. The stock has risen about 5.2% over the last week and 31.5% over the past month, and is now up 40.6% year to date, even though longer-term returns over 3 and 5 years remain slightly negative. Recent headlines have focused on shifting steel demand expectations, ongoing trade policy discussions, and...

Noble (NYSE:NE) just made a decisive move, agreeing to sell six jackup rigs and lean harder into deepwater and ultra harsh work, a shift that could meaningfully reshape its risk profile and cash generation. See our latest analysis for Noble. Those jackup sales land after a choppy stretch, with the share price down year to date but still delivering a positive one year total shareholder return. This suggests sentiment is cautious even as interest in Noble’s streamlined, deepwater focused story...

In early December 2025, BitMine Immersion Technologies disclosed that it had purchased more than 138,000 ether in a week, lifting its Ethereum treasury to about 3.86 million ETH and over US$13.20 billion in combined crypto and cash assets, or more than 3.2% of Ethereum’s circulating supply. Beyond amassing the world’s largest corporate Ethereum position, BitMine is targeting control of 5% of the ETH supply and preparing a US-based staking infrastructure launch in 2026, signaling ambitions...

If you are wondering whether United Parcel Service is a bargain or a value trap at current levels, you are not alone. This breakdown is designed to cut through the noise for long-term investors. Despite a tough longer-term picture, with the stock down 18.9% year to date and 16.7% over the past year, UPS has bounced 6.0% in the last week and 5.7% over the past month as sentiment has started to thaw. That shift comes as investors refocus on UPS's leverage to global e-commerce volumes and the...

If you have been wondering whether AstraZeneca is still worth buying after its big run, you are not alone. This article is all about unpacking what that price actually implies. The stock is up 0.6% over the last week, 1.0% over the last month, and 27.9% year to date, adding to a 31.4% 1 year gain and more than doubling over 5 years with a 102.2% return. Those moves have been underpinned by a steady stream of pipeline and regulatory updates, together with ongoing progress in its core oncology...

Tandem Diabetes Care (TNDM) is back in focus after fresh commentary underscored two pressure points: soft insulin pump demand over the past couple of years and a still negative EBITDA profile that limits financial flexibility. See our latest analysis for Tandem Diabetes Care. Despite those concerns, the market has started to rethink Tandem’s prospects, with a 30 day share price return of 19.69 percent and a striking 90 day share price return of 70.90 percent. However, the 1 year total...

Wondering if Campbell's dip has finally turned this pantry staple into a genuine value opportunity, or if it is a value trap in disguise? The stock has slid about 3.2% over the last week and roughly 9.9% over the past month, capping off a much steeper slide of around 32.4% year to date and 30.8% over the last year. Recent headlines have focused on shifting consumer spending habits, with shoppers trading between brand names and private labels, as well as ongoing debates about how inflation...

Earlier this month, UBS initiated coverage on Stifel Financial with a positive analyst rating, highlighting the firm’s evolution into a globally competitive wealth manager, investment bank, and brokerage under CEO Ronald Kruszewski, following a series of acquisitions. This endorsement from a major global institution underscores how Stifel’s multi-year transformation and diversified business model are increasingly drawing attention from large, institutional research desks. Now we’ll examine...

Enel (BIT:ENEL) just secured the entire 3.36 TWh per year on offer in Chile's latest national power tender, locking in multi year power purchase agreements that improve cash flow visibility and strengthen its presence in Chile. See our latest analysis for Enel. That backdrop of long term power contracts in Chile, plus recent affirmations of group credit strength, helps explain why Enel’s share price return is up strongly year to date and its multi year total shareholder return still looks...

Cisco Systems (CSCO) has quietly put together a steady run, with shares up roughly 19% over the past 3 months and about 38% over the past year, drawing fresh attention from long term investors. See our latest analysis for Cisco Systems. That steady climb to a recent share price of $79.27, including a roughly double digit 30 day share price return and a strong multi year total shareholder return, suggests momentum is building as investors warm to Cisco’s growth and earnings profile. If Cisco’s...